The Latest Cardiac and Vascular News
Funding supports commercial expansion of inHEART’s digital twin of the heart in the US, EU, Asia Pacific, and Middle East markets, as well as the development of new software solutions across the cardiac care continuum CAMBRIDGE, Mass. and BORDEAUX, France, May 6, 2024 /PRNewswire/ –…
IRVINE, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the upcoming Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024, at 11:20 AM Pacific Time.
WEST VALLEY CITY, Utah, May 6, 2024 /PRNewswire/ — Scientia Vascular, a leader in neurovascular innovation, is thrilled to announce the FDA clearance of two uniquely engineered catheters: the Plato 17—a DMSO-compatible microcatheter—and the Socrates 38, an aspiration catheter engineered…
Experts in Vascular Surgery, Interventional Radiology and Interventional Cardiology to Help Guide Commercialization SAN DIEGO, May 6, 2024 /PRNewswire/ — Provisio Medical, Inc. today announced the formation of a Physician Advisory Board (PAB) comprising a multidisciplinary group of…
NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 30,000 of NewAmsterdam’s ordinary shares to three non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
Westport, CT, May 03, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or “the Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced new appointments to its now fully constituted board of directors (the “Board”), which is comprised of a total of five (5) directors, three (3) of whom are classified as independent directors. The final compositions of the committees to the Board will be determined in the very near term.
Medtronic, the global leader in healthcare technology, today announced the release of important clinical outcomes in two leading transcatheter valve therapies. The results for these studies were presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions in Long Beach, CA. “The data presented at SCAI 2024 reinforces […]
WAYNE, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics, Inc., a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today presented final results from the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) of its lead gene therapy candidate XC001 (encoberminogene rezmadenovec) for refractory angina at the Society for Cardiovascular Angiography […]
BURLINGTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided guidance.
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results. “We are proud to announce a strong start to 2024, marked by growth across each of our […]
